Program
CG-7321
A development code.
Its studies are mostly in Breast Neoplasms, led by Chengdu Cynogen Bio-pharmaceutical Tech..
Furthest: phase 1, since Oct 27, 20261 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chengdu Cynogen Bio-pharmaceutical Tech. | 11 open or running | phase 1since Oct 27, 2026 | Oct 27, 2026 | Apr 2027phase 1 · NCT07923214 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 27, 2026First study: phase 1 study in Breast NeoplasmsFirst studyNCT07923214 · 66 planned · China
Ahead
- Apr 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07923214
TargetBeta
“CG-7321 is a novel oral small molecule CDK2 inhibitor with balanced CDK4/6/9 inhibition potency, being developed for the treatment of advanced solid tumors, being developed for the treatment of advanced solid tumors.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07923214Breast Neoplasms · China | 1 | Recruiting | Apr 2027 | 66 |
How it is read
Names in the registry
- “CG-7321”, 1 entry
Codes read as this program: CG7321.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.